For example, orlistat is an intestinal lipase inhibitor indicated for the treatment of obesity; statins are inhibitors of the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase that are used to treat dyslipidemia due to their lipid-lowering effect; glucagon-like peptide (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors increase incretins and are approved for the treatment of diabetic patients. This evidence concerns the gene DPP4 and metabolic syndrome.